Rafarma Pharmaceuticals(OTC) RAFA

Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise focused on manufacturing and distributing a variety of medicinal products, primarily within the Russian market. The company specializes in generic antibiotics and specialized drugs, including anti-cancer medications and non-beta-lactam antibiotics.

Products and Services

• Manufactures generic antibiotics and specialized drugs
• Develops treatments for injuries and ocular inflammatory conditions
• Collaborates on medical cannabis suppositories for inflammatory bowel disease

Growth Outlook

• Recent quarterly revenue of $302,000 shows consistent demand
• Trailing twelve months (TTM) net income margin of 3.23% indicates profitability
• Strong operating income ratio of 29.14% reflects operational efficiency

Financial Highlights

• TTM revenue of $3.1 million demonstrates growth potential
• Current ratio of 1.09 suggests good short-term financial health
• Price-to-earnings ratio of 10.43 indicates attractive valuation

Rafarma Pharmaceuticals, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, and has established a solid presence in the Russian market. The company's diverse product portfolio includes a range of medicinal products, which positions it well to meet the growing demand for pharmaceuticals. The recent quarterly revenue figures indicate a stable performance, while the TTM net income margin suggests that the company is effectively managing its costs and generating profits. The current ratio of 1.09 indicates that Rafarma has sufficient assets to cover its short-term liabilities, which is a positive sign for potential investors. Additionally, the price-to-earnings ratio of 10.43 may suggest that the stock is undervalued compared to its earnings potential, making it an interesting option for those looking to invest in the pharmaceutical sector. Overall, Rafarma Pharmaceuticals, Inc. presents a compelling case for investors interested in a company with a strong operational foundation and growth potential in the pharmaceutical market.